Moleculin Biotech (MBRX) has released an update to notify the public and investors about a regulation fd disclosure.
Moleculin Biotech, Inc. issued a press release on January 24, 2024, revealing preliminary data from its 2023 Annamycin clinical trials and outlining expectations for 2024, including multiple data readouts and a progression to pivotal Phase 2B/3 clinical studies. The company also updated its upcoming milestones, with the details of the press release incorporated by reference in a recent report. The content shared is for informational purposes and is not intended to be filed under the Securities Exchange Act of 1934 or the Securities Act of 1933.
For further insights into MBRX stock, check out TipRanks’ Stock Analysis page.
